|Dr. John A. Scarlett||CEO, Pres & Chairman||1.03M||N/A||1951|
|Ms. Olivia Kyusuk Bloom||Exec. VP of Fin., CFO & Treasurer||644.72k||N/A||1969|
|Dr. Andrew J. Grethlein||Exec. VP & COO||653.5k||N/A||1964|
|Mr. Stephen N. Rosenfield||Exec. VP, Chief Legal Officer & Corp. Sec.||518.12k||4.3M||1950|
|Ms. Melissa A. Kelly Behrs||Exec. VP & Chief Bus. Officer||610.28k||N/A||1964|
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
Geron Corporation’s ISS Governance QualityScore as of July 29, 2019 is 6. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 8; Compensation: 9.